ClinicalTrials.gg
RecruitingNCT06010927Updated Sep 15, 2023

Effect of Ketamine/Midazolam Premedication Versus Pre-extubation Ketofol on Recovery Profile in Pediatrics Undergoing Adenotonsillectomy.

A Phase 4 interventional study of ketamine/midazolam and Ketofol in Emergence Delirium, sponsored by Cairo University. Recruiting at 2 sites in Egypt. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Cairo University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2023, 3 years ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing ketamine in Emergence Delirium — 7 open to participants now, 8 under way, none of them phase 3. Ketamine · Emergence Delirium.

Planned enrollment
4th of 16
140 · median 90
Started
2023
with 2 others
Phase 4
5 of 16
2 open now
Registered
8th of 16
by date
Lead sponsor
3 of 16
Cairo University

Among the 16 studies testing ketamine in Emergence Delirium, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 5 in phase 4, and was the 8th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

7 of the 16 studies testing ketamine in Emergence Delirium are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ketamine in Emergence Delirium, or all of them as a file.
02

Study summary

An optimum recovery profile after AT includes a rapid, smooth awakening without emergence agitation (EA), stable vital signs and oxygenation, reduced postoperative nausea and vomiting (PONV), controlled postoperative pain, and patient or parents' satisfaction. Ketamine is a low-cost drug with a wide therapeutic window. Ketamine is a competitive N-methyl-D-aspartate receptor antagonist with good analgesic properties and periprocedural amnesia.

The ketamine/midazolam combination was administered in different ways with controversial results about their effect on the EA and recovery profile.

Ketofol, a mixture of ketamine and propofol, has been used in different favorable recovery profiles regarding postoperative EA and PONV.

This study aims to evaluate the effect of premedication with an intramuscular ketamine/ midazolam combination versus pre-extubation ketofol on the EA and the recovery profile.

03

Conditions studied

  • Emergence Delirium

Browse trials for

04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I or II
  • Children scheduled for AT under general anesthesia (GA).

Exclusion criteria

Exclusion Criteria:

  • Congenital cardiovascular anomalies
  • Behavioral changes
  • Delayed physical development
  • Children receiving sedatives or anticonvulsants therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Group-A; ketamine/midazolam premedication

    Drug: ketamine/midazolam

  • Active comparator
    Group-B: Ketofol pre-extubation

    Drug: Ketofol

Interventions

06

What researchers measure

Primary outcomes

  1. incidence of Emergence agitation

    Time frame: starting from time of PACU admission after recover from anesthesia till 6 hours postoperative

07

Study locations

2 of 2 sites recruiting
  • Abeer Ahmed
    Maadi, Cairo 11562, Egypt
    Recruiting
  • Anesthesia department - Faculty of medicine- Cairo University
    Cairo, Egypt
    Recruiting
    • Abeer Ahmed, Anesthesia lecturer · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Nov 2023, 3 months after the start.

Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 3 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Aug 25, 2023
StartActual
Aug 25, 2023
Primary completionEst.
Nov 2023
CompletionEst.
Dec 2023
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06010927
Lead sponsor
Cairo University
Responsible party
Abeer Ahmed, MD (Professor, Cairo University) — Principal investigator
First posted
Aug 25, 2023
Start date
Aug 25, 2023
Primary completion
Nov 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Sep 15, 2023

Study contacts

Abeer Ahmed
Contact
abeer_ahmed@kasralainy.edu.eg
01005244590

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketamine · Midazolam · Ketofol

Start the discussion